scholarly journals Prostate-specific antigen as a marker for prostate diseases and a target for drug therapy (literature review)

2017 ◽  
Vol 19 (7) ◽  
pp. 35-40
Keyword(s):  
Drug Therapy ◽  
Literature Review ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Prostate Diseases

scholarly journals Eight Days of Water-Only Fasting Promotes Favorable Changes in the Functioning of the Urogenital System of Middle-Aged Healthy Men

Nutrients ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 113
Author(s):  
Sławomir Letkiewicz ◽  
Karol Pilis ◽  
Andrzej Ślęzak ◽  
Anna Pilis ◽  
Wiesław Pilis ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Prostate Specific Antigen ◽  
Lower Urinary Tract ◽  
Specific Antigen ◽  
Blood Levels ◽  
Urinary Flow ◽  
Urogenital System ◽  
Middle Aged ◽  
Prostate Diseases ◽  
Lower Urinary

The aim of this study was to determine whether, after 8 days of water-only fasting, there are changes in the efficiency of the lower urinary tract, the concentration of sex hormones, and the symptoms of prostate diseases in a group of middle-aged men (n = 14). For this purpose, before and after 8 days of water-only fasting (subjects drank ad libitum moderately mineralized water), and the following somatic and blood concentration measurements were made: total prostate specific antigen (PSA-T), free prostate specific antigen (PSA-F), follicle stimulating hormone (FSH), luteotropic hormone (LH), prolactin (Pr), total testosterone (T-T), free testosterone (T-F), dehydroepiandrosterone (DHEA), sex hormone globulin binding (SHGB), total cholesterol (Ch-T), β-hydroxybutyrate (β-HB). In addition, prostate volume (PV), volume of each testis (TV), total volume of both testes (TTV), maximal urinary flow rate (Qmax), and International Prostate Symptom Score (IPSS) values were determined. The results showed that after 8 days of water-only fasting, Qmax and IPSS improved but PV and TTV decreased significantly. There was also a decrease in blood levels of PSA-T, FSH, P, T-T, T-F, and DHEA, but SHGB concentration increased significantly. These results indicate that 8 days of water-only fasting improved lower urinary tract functions without negative health effects.

scholarly journals Solitary Lung Metastasis From Primary Prostate Cancer With Normal Prostate Specific Antigen Level: a Case Report and Literature Review

2021 ◽  
Author(s):  
Natsumi Maru ◽  
Asako Okabe ◽  
Haruaki Hino ◽  
Takahiro Utsumi ◽  
Hiroshi Matsui ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Literature Review ◽  
Prostate Specific Antigen ◽  
Lung Metastasis ◽  
Specific Antigen ◽  
Prostate Specific Antigen Level ◽  
Low Grade ◽  
Antigen Level ◽  
Normal Prostate ◽  
Term Survival

Abstract Background: Pulmonary involvement from prostate cancer is a well-known condition, but solitary lung metastasis is rare, with its associated clinical characteristics not yet fully elucidated.Case presentation: A 77-year-old man, with a history of radical prostatectomy for primary prostatic carcinoma 14 years prior, presented to our institution with a low-grade fever. Upon consultation, biochemical recurrence was suspected due to a gradual increase in prostate-specific antigen level. Salvage radiation therapy was considered but not performed since there was no recurrent macroscopic tumor. Computed tomography showed a solitary nodule with spiculation located on the upper lobe of the left lung while positron emission tomography suggested malignancy without metastasis. Based on these findings, primary lung cancer was suspected and thoracoscopic left upper lobectomy with lymph node dissection was performed. Pathological diagnosis of the tumor was a solitary lung metastasis of prostate cancer. The postoperative recovery was uneventful. Conclusion: We report a case with normal prostate-specific antigen level, along with a literature review. According to previous case reports, there are some pitfalls leading misdiagnosis as a primary lung tumor. However, we consider that surgical resection is associated with increased diagnostic accuracy and long-term survival.

scholarly journals Development of immunoradiometric assay for quantitative determination of free prostate-specific antigen

2005 ◽  
Vol 24 (2) ◽  
pp. 129-134 ◽  
Author(s):  
Miroslava Jankovic ◽  
Maja Kosanovic ◽  
Ljiljana Hajdukovic-Dragojlovic ◽  
Snezana Golubovic
Keyword(s):  
Quantitative Determination ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Laboratory Diagnostics ◽  
Immunoradiometric Assay ◽  
Serum Samples ◽  
Coefficients Of Variation ◽  
One Step ◽  
Prostate Diseases

In this study we reported the development and analytical validation of new assay for quantitative determination of free prostate-specific antigen, fPSA. It is formulated as one step, two-site "sandwich" immunoradiometric assay. Specificity of this assay was achieved by using epitope-1-reactive anti-fPSA antibody as tracer antibody. Assay was calibrated against first international standard 96/668, and its detection limit was determined as 0.08 mg/L. Intra- and inter-assay coefficients of variation were 3.42-7.53% and 7.04-8.33%, respectively. Measured concentrations of serially diluted serum samples were close to the calculated concentrations, indicating good linearity with recovery percentage ranging from 98.7-107.4%. Analytical performance characteristics of fPSA assay speaks in favor of its use as a reliable tool in laboratory diagnostics relating to prostate diseases.

scholarly journals Prostate Specific Antigen Detection Using Microgapped Electrode Array Immunosensor with Enzymatic Silver Deposition

2009 ◽  
Vol 55 (5) ◽  
pp. 964-971 ◽  
Author(s):  
Yong Huang ◽  
Tai-Hong Wang ◽  
Jian-Hui Jiang ◽  
Guo-Li Shen ◽  
Ru-Qin Yu
Keyword(s):  
Prostate Specific Antigen ◽  
Limit Of Detection ◽  
Specific Antigen ◽  
Electrical Conductance ◽  
Electrode Array ◽  
Serum Samples ◽  
Silver Deposition ◽  
Low Concentrations ◽  
Chemiluminescent Immunoassay ◽  
Prostate Diseases

Abstract Background: Analysis of trace proteins plays an essential role in the fields of biomedical research and clinical diagnosis. Development of methods for the detection of proteins at very low concentrations has historically been a challenge in immunochemistry. We have developed an electrical immunosensor for the detection of prostate specific antigen (PSA). Methods: The electrical immunosensor uses a microgapped interdigitated electrode array (MGIDEA) based on enzymatic silver deposition reaction. The deposition of silver was dispersed over the microgaps and allows the microgapped interdigitated electrodes to be electrically connected, resulting in an increase in electrical conductance of MGIDEA that is used to quantify the analyte concentration. We used this electrical immunosensor to measure PSA in human serum samples from patients with prostate diseases. Results: This electrical immunosensor exhibited a linear response with PSA concentrations over a 6-decade range from 1.0 pg/L to 1.0 μg/L, with detection limit of 0.9 pg/L. PSA concentrations using this immunosensor agreed within 10% of those obtained using a commercial chemiluminescent immunoassay. Conclusions: The MGIDEA method has characteristics (analyte specific, low background, low limit of detection) that provide potential for molecular detection in various biomedical areas.

scholarly journals Urinary prostate specific antigen: Is the clinical use likely?

2005 ◽  
Vol 52 (4) ◽  
pp. 69-74 ◽  
Author(s):  
T. Pejcic ◽  
J. Hadzi-Djokic ◽  
M. Acimovic ◽  
C. Topuzovic ◽  
B. Milkovic ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Prostate Specific Antigen ◽  
Androgen Deprivation Therapy ◽  
Specific Antigen ◽  
Androgen Deprivation ◽  
Trus Biopsy ◽  
Significant Difference ◽  
Prostate Diseases

Prostate specific antigen (PSA) blood test represents the standard procedure in prostate cancer (CaP) diagnosis and follow-up. However, determination of PSA in the urine, where PSA is present in much higher concentrations than in the blood, still remains in the field of research. Objectives: To determine urinary concentrations of PSA (uPSA) in different groups of patients (pts.), and to estimate is it possible to differentiate benign and malignant prostate diseases and to follow-up the results of treatment. Methods: Between January 2001. and November 2003., urinary concentrations of PSA were determined at 142 pts. divided in seven groups: 1. young and healthy volunteers, 2. "BPH-24": pts. with benign prostatic hyperplasia (BPH) who collected the sample of 24- hour voided urine, 3. "BPH-I": pts. with BPH who collected the first portion of first urinary voiding, 4. "TRUS-CaP": pts. with CaP which gave the first portion of urine just prior to transrectal ultrasound guided prostate biopsy (TRUS- biopsy), 5. "TRUSnon- CaP": pts. who gave first portion of urine prior to TRUS-biopsy, but biopsy did not prove the presence of CaP, 6. "RRP": pts. who underwent radical retropubic prostatectomy (RRP), 7. "AAT": pts. who underwent androgen deprivation therapy. Results: Average uPSA value in the group of young and healthy volunteers, was 13.8+19.6 ng/ml, in "BPH-24": 38.0+ 44.4 ng/ml, in "BPH-I": 140.8+140.9 ng/ml, in "TRUSCaP": 234.8+277.7 ng/ml, in TRUS-non-CaP: 113.1 +148.5 ng/ml, and in the group "RRP": 4.4+4.7 ng/ml. There was no statistically significant difference of average uPSA values between "BPH-I" and "TRUSCaP" groups. The significant difference was found between the group of young volunteers and "BPH-I". In "TRUS-CaP" group, there was strong correlation between tumor size and aggressiveness and uPSA concentration. Finally, PSA and uPSA decline during androgen deprivation therapy, strongly correlated (up to r=0.95). Conclusions: Determination of uPSA cannot differentiate BPH and CaP. However, in the group of pts. with proven localized CaP, uPSA can provide additional information concerning T-staging. Moreover, simultaneous monitoring of PSA and uPSA response on hormonal therapy, can provide an early recognition of androgen-in different CaP (AIPCA) and hormone resistant CaP (HRPCA).

scholarly journals A STUDY ON CORRELATION OF SERUM PROSTATE SPECIFIC ANTIGEN WITH CLINICAL AND PATHOLOGICAL VARIABLES IN PATIENTS OF PROSTATOMEGALY

2021 ◽  
Vol 5 (10) ◽  
Author(s):  
Sanjay Patidar ◽  
Kritika Kamal ◽  
Jaydip Sinh Kathota ◽  
Sudhanshu Tiwari ◽  
Prashant Nakrani
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Cancer Detection ◽  
Specific Antigen ◽  
Digital Rectal Examination ◽  
Age Group ◽  
Rectal Examination ◽  
Carcinoma Prostate ◽  
Total Psa ◽  
Prostate Diseases

Background: In clinical practice, biopsies are generally performed only when the results ofprostate specific antigen (PSA) test or digital rectal examination (DRE) are abnormal. This leads to misdiagnosis of most small prostatic cancers present in many older men. Patients with lower urinary tract infection (LUTS) who have serum PSA levels higher than 4ng/ml are primarily advised to undergo prostate biopsy to rule out cancer. However, PSA is organ specific not disease specific, so the presence of other prostate diseases such as benign prostatic hyperplasia (BPH) and prostatitis may influence its effectiveness for cancer detection. Hence, the PSA based prostate cancer detection is fraught with high false positive rate. Aim:To evaluate the utility of PSA assay as a method of investigation in diagnosis of prostatic lesion. Objectives: The use of Serum PSA levels for the early detection of prostate cancer and evaluate its role with other modalities for diagnosis of prostate cancer and to diagnose different diseases of prostate, i.e. prostatitis, BPH in prostatomegaly, and its correlation with Serum PSA levels. Materials and Methods: This prospective descriptive study was conducted in Index Medical College, Hospital & Research Centre, Indore, M.P,India in the period of August 2019 to July 2021. The patients were selected from the outdoor Department of General Surgery. Results: A total of 80 male patients presenting with LUTS were included. Their mean age was 68.66 years. The majority i.e. 41 of the study group were in the age group of 61-70 years. 42 of patients had Serum PSA < 4ng/ml. Biopsy proven adenocarcinoma cases 34% of the cases are in the age group of 61-70 years. Out of the biopsy proven adenocarcinoma cases, DRE was suspicious of malignancy in 89%. Conclusion: Serum PSA levels have a significant correlation with the age group, with the increase in age there is rise in Serum PSA levels. Transabdominal ultrasound, DRE and Serum PSA has high sensitivity in diagnosis of prostatomegaly but it was found that none of the screening tool has got much efficacy in differentiating carcinoma prostate from benign hypertrophy, but the combination of DRE and Serum total PSA or DRE, Serum total PSA and ultrasound abdomen showed higher efficacy in diagnosis of carcinoma prostate. Increase in Serum PSA is directly related to carcinoma, but there is no absolute cut-off for Serum PSAfor diagnosis of carcinoma. Key-Words: Prostate specific antigen, Prostatomegaly, Benign Prostatic Hypertrophy, Digital Rectal Examination, International Prostate Severity Score, Carcinoma Prostate.

scholarly journals Highly Selective Optical Sensor Eu (TTA)3 Phen Embedded in Poly Methylmethacrylate for Assessment of Total Prostate Specific Antigen Tumor Marker in Male Serum Suffering Prostate Diseases

2020 ◽  
Vol 8 ◽  
Author(s):  
Mohannad Garoub ◽  
A. H. Hefny ◽  
W. E. Omer ◽  
Mostafa M. Elsaady ◽  
Mohamed M. Abo-Aly ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Optical Sensor ◽  
Low Cost ◽  
Aqueous Media ◽  
Specific Antigen ◽  
Resonance Energy Transfer ◽  
Resonance Energy ◽  
Total Prostate Specific Antigen ◽  
Prostate Diseases

A low-cost, simple, and highly selective method was used for the assessment of total prostate specific antigen (tPSA) in the serum of prostate cancer patients. This method is based on quenching the intensity of luminescence displayed by the optical sensor Eu (TTA)3 phen/poly methylmethacrylate (PMMA) thin membrane or film upon adding different concentrations of tPSA. The luminescent optical sensor was synthesized and characterized through absorption, emission, scanning electron microscopy (SEM), and x-ray diffraction (XRD), and is tailored to present red luminescence at 614 nm upon excitation at 395 nm in water. The fabricated sensor fluorescence intensity is quenched in the presence of tPSA in aqueous media. The fluorescence resonance energy transfer (FRET) is the main mechanism by which the sensor performs. The sensor was successfully utilized to estimate tPSA in the serum of patients suffering prostate cancer in a time and cost effective way. The statistical results of the method were satisfactory with 0.0469 ng mL−1 as a detection limit and 0.99 as a correlation coefficient.

Sign in / Sign up

Export Citation Format

Share Document